Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Nov 16;17(1):177.
doi: 10.1186/s12882-016-0391-7.

Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial

Matthew A Roberts  1   2 , Louis Huang  1   2 , Darren Lee  1   2 , Robert MacGinley  1   2 , Stefanie M A Troster  2 , Annette B Kent  1   2 , Sukhvinder S Bansal  3 , Iain C Macdougall  4 , Lawrence P McMahon  5   6
Affiliations
Randomized Controlled Trial

Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial

Matthew A Roberts et al. BMC Nephrol. .

Abstract

Background: Intravenous iron affects serum levels of intact fibroblast growth factor-23 (iFGF23) and its cleavage product c-terminal FGF23 (cFGF23) in iron-deficient people with normal renal function. We hypothesized that intravenous iron modulates iFGF23 and cFGF23 in haemodialysis patients differently according to the type of iron used.

Methods: Prevalent, stable haemodialysis patients requiring protocol-based intravenous iron therapy were randomized to a single 200 mg dose of either ferric carboxymaltose (FCM) or iron sucrose (IS). The primary outcome was change in iFGF23 and cFGF23 from pre-infusion to Day 2 post-infusion. Serum hepcidin, ferritin and phosphate were also measured. Pair-wise comparisons utilised the Wilcoxon rank sum test; linear mixed models with an interaction term for treatment and time evaluated between-group effects.

Results: Forty-two participants completed the study. In those randomized to FCM (n = 22), median (interquartile range) values pre-infusion and Day 2, respectively, were 843 pg/mL (313-1922) and 576 pg/mL (356-1296, p = 0.05) for iFGF23, 704RU/mL (475-1204) and 813RU/mL (267-1156, p = 0.04) for cFGF23, and 1.53 mmol/L (1.14-1.71) and 1.37 (1.05-1.67, p = 0.03) for phosphate. These parameters did not change following IS. Both serum ferritin (p < 0.001) and hepcidin (p < 0.001) increased in both groups, and the increase in hepcidin was greater in the FCM group (p = 0.03 for between-group difference).

Conclusions: Contrary to iron-deficient people with normal renal function, haemodialysis patients given protocol-driven intravenous FCM demonstrated a fall in iFGF23 and a rise in cFGF23, changes not evident with IS. This suggests a differential effect of intravenous iron treatment according to both formulation and renal function.

Trial registration: Australian and New Zealand Clinical Trials Register ACTRN12614000548639 . Registered 22 May 2014 (retrospectively registered).

Keywords: Fibroblast growth factor-23; Haemodialysis; Hepcidin; Iron infusion; Randomized controlled trial.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
CONSORT Flow diagram of patient enrolment
Fig. 2
Fig. 2
Median (interquartile range) levels over the course of the study of iFGF23 (pg/mL), cFGF23 (RU/mL) and phosphate (mmol/L) in participants treated with iron sucrose (left panels) and ferric carboxymaltose (right panels)
Fig. 3
Fig. 3
Median (interquartile range) levels over the course of the study of serum hepcidin (ng/mL), ferritin (μg/L) and haemoglobin (g/L) in participants treated with iron sucrose (left panels) and ferric carboxymaltose (right panels)
Fig. 4
Fig. 4
Median levels of cFGF23 over time in participants with low (<500 mL) daily urine output (left panel) and higher (≥500 mL) daily urine output (right panel)
See this image and copyright information in PMC

References

    1. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370–8. doi: 10.1038/ki.2011.47. - DOI - PMC - PubMed
    1. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584–92. doi: 10.1056/NEJMoa0706130. - DOI - PMC - PubMed
    1. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305(23):2432–9. doi: 10.1001/jama.2011.826. - DOI - PMC - PubMed
    1. Wolf M, White KE. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens. 2014;23(4):411–9. doi: 10.1097/01.mnh.0000447020.74593.6f. - DOI - PMC - PubMed
    1. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci. 2011;108(46):E1146–55. doi: 10.1073/pnas.1110905108. - DOI - PMC - PubMed

Publication types